<乌鸦传媒>R-CHOP Toppled in First-Line DLBCL Trial Replacing vincristine with polatuzumab vedotin improved PFS, without adding toxicity Dec 14, 2021
<乌鸦传媒>R2 Maintenance for Elderly MCL Patients Worth the Risk? Longer PFS with addition of lenalidomide to rituximab, but also more toxicity Dec 13, 2021
<乌鸦传媒>Novel Bispecific Antibody Nets Durable Remissions in Follicular Lymphoma Mosunetuzumab offers "clinically meaningful outcomes" in relapsed/refractory disease Dec 12, 2021
<乌鸦传媒>CAR T-Cell Therapy Makes Strong Case for Earlier Use in Lymphoma Large increases in event-free survival with two CAR T-cell products in second line Dec 11, 2021
<乌鸦传媒>Chemo-Free Regimen Highly Active in Older Mantle Cell Lymphoma Patients Overall response rate of 96% with ibrutinib-rituximab, but cardiotoxicity a possible issue Nov 29, 2021
<乌鸦传媒>Novel Triplet Yields Undetectable MRD Status in 90% of CLL/SLL Patients Zanubrutinib plus obinutuzumab and venetoclax was also well tolerated Nov 29, 2021
<乌鸦传媒>Ceritinib Shows Promise in ALK-Positive Pediatric Malignancies Responses seen in neuroblastoma, among other tumors Nov 17, 2021
<乌鸦传媒>Ibrutinib Boosts Survival in Younger Patients With Certain DLBCL Subtypes New analysis "casts the PHOENIX trial in a new light," authors say Nov 04, 2021
<乌鸦传媒>Ibrutinib-Rituximab Wins Out in Waldenstrom's Macroglobulinemia Risk of disease progression or death reduced by 75% versus rituximab alone Oct 11, 2021
<乌鸦传媒>9/11 Responders Face Higher Risk of Multiple Cancers Longer follow-up sheds light on the long-term consequences of exposure to disaster site Sep 10, 2021
<乌鸦传媒>Lymphoma in RA: Disease Activity Matters Strongest risk factors were baseline disease activity scores and bone erosions Sep 08, 2021
<乌鸦传媒>Non-Chemo Regimen Highly Active in R/R Hodgkin Lymphoma Three-year progression-free survival of 77%, including 91% after stem-cell transplantation Aug 23, 2021
<乌鸦传媒>How CAR T-Cell Therapy Measures Up in Follicular Lymphoma Better response rates and survival with axicabtagene ciloleucel versus external control group Jun 15, 2021
<乌鸦传媒>COVID Vaccine Protection; 'Until You Die From the Cancer'; What's Palliative Care? News, features, and commentary about cancer-related issues Jun 10, 2021
<乌鸦传媒>Another CAR-T Impresses in Follicular Lymphoma Complete responses in 66% of patients with relapsed or refractory disease Jun 08, 2021
<乌鸦传媒>Thiotepa-Based Conditioning Promising for Primary CNS Lymphoma Commonly used regimens with autologous transplant improved survival May 06, 2021
<乌鸦传媒>Add-On PI3K Inhibitor Wins in Relapsed, Indolent NHL Adding copanlisib to rituximab also doubled CR rate, with manageable toxicity Apr 10, 2021
<乌鸦传媒>Op-Ed: Blood Cancer Patients Need More COVID Vax Answers Patients are left wondering, "will I be protected?" Mar 24, 2021
<乌鸦传媒>Anti-CD20 Drugs Tied to Severe COVID in Cancer Patients Plus: Active chemo treatment may not be a COVID risk factor Feb 05, 2021
<乌鸦传媒>JAK Inhibitor Misses Endpoint in Safety Study. Now What? Major blow to popular class of oral rheumatology drugs Jan 27, 2021
<乌鸦传媒>Non-Hodgkin Lymphoma: Bispecific Antibodies Impress in Refractory Disease Odronextamab, epcoritamab surpass 90% response threshold in early trials Dec 11, 2020
<乌鸦传媒>Blood Cancers and COVID-19: 'A Medically Vulnerable' Group Patients with hematologic malignancies and SARS-CoV-2 face higher risks for infection, death Dec 06, 2020
<乌鸦传媒>HIV: Don't Quit on Hope, Says 'London Patient' IAC roundtable addresses prospects for cure, now proven to be possible Jul 06, 2020
<乌鸦传媒>Minimal Link Between Eczema and Most Cancers Study finds severe eczema tied to small risk for lymphoma Jun 30, 2020
<乌鸦传媒>Cancer Immunotherapy Tied to Severe COVID-19 Outcomes Nearly threefold increased risk of hospitalization, severe respiratory illness Jun 25, 2020
<乌鸦传媒>Worse Blood Cancer Outcomes in Hispanics Diagnosis at earlier age, worse survival, especially for those on U.S.-Mexico border Jun 24, 2020
<乌鸦传媒>Keytruda Tops Adcetris in Head-to-Head Hodgkin's Trial Checkpoint inhibitor improved PFS in refractory and transplant-ineligible cases Jun 15, 2020
<乌鸦传媒>CAR T-Cell Therapy Impresses in Indolent NHL Overall response rate exceeding 90% with axi-cel in relapsed/refractory setting May 31, 2020
<乌鸦传媒>Nivolumab-Based Tx Effective in Early, Unfavorable Hodgkin's Interim results showed high CR rates and almost 100% PFS, OS at 12 months May 01, 2020
<乌鸦传媒>COVID-19 Mortality Spikes in Patients With Lung, Blood Cancers Those with metastatic disease also at special risk for poor outcomes Apr 28, 2020
<乌鸦传媒>DOAC Works in Cancer-Related VTE, No Tradeoff in Bleeds Apixaban monotherapy matches dalteparin in non-inferiority trial Mar 29, 2020
<乌鸦传媒>New CAR-T Makes Case for Aggressive Lymphomas Largest trial to date shows 73% ORR, 53% CR, potential for outpatient treatment Feb 25, 2020
<乌鸦传媒>Stem-Cell Transplant Trial Ends in a Draw Similar PFS with haploidentical bone marrow, double unrelated umbilical cord blood Feb 24, 2020
<乌鸦传媒>Preemptive Anti-IL-6 May Cut Severe CRS With CAR-T Tx Targeting patients with high tumor burden reduced severe CRS by 50% Feb 22, 2020
<乌鸦传媒>Higher Risk of Shingles Seen in Patients With Certain Cancers Vaccine development may help with prevention of herpes zoster in this population Dec 31, 2019
<乌鸦传媒>'Off-the-Shelf' Therapy Active After CAR T-Cell Failure Bispecific antibody mosunetuzumab targets CD3, CD20; needs no ex vivo T-cell processing Dec 07, 2019
<乌鸦传媒>No Cancer Risk Found With TNF Inhibitors in Psoriatic Arthritis Expected cancer cases similar to those in general populace, study shows Jun 13, 2019
<乌鸦传媒>Rheumatologist's Primer on Checkpoint Inhibitors Specialist reviews the landscape of cancer drugs' autoimmune side effects Apr 09, 2019
<乌鸦传媒>Durable Responses With Keytruda in Later-Line SCLC Plus umbralisib in marginal zone lymphoma and a next-generation TRK-targeted agent Apr 04, 2019
<乌鸦传媒>Do Keloids Convey a Higher Cancer Risk? Taiwanese researchers show association between raised scars and cancers Mar 03, 2019
